Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein.
The Company's novel platform technology is based on over twenty years of pre-clinical research by Yvonne Paterson, Professor of Microbiology, University of Pennsylvania, and Fellow of the American Academy for the Advancement of Science.